<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3368">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605887</url>
  </required_header>
  <id_info>
    <org_study_id>0328-20-RMB</org_study_id>
    <secondary_id>MOH_2020-11-02_009463</secondary_id>
    <nct_id>NCT04605887</nct_id>
  </id_info>
  <brief_title>Angiotensin 1-7 as a Therapy in the Treatment of COVID-19</brief_title>
  <official_title>Angiotensin 1-7 as a Therapy for Pneumonia Caused by Coronavirus 2(SARS-CoV-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Constant Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 ,double blind, randomized study of therapy with Angiotensin 1-7 in COVID-19 patients.&#xD;
      120 confirmed SARS-CoV-2 infected patients who exhibit moderate- clinical symptoms including&#xD;
      dyspnea, cough and fever, hospitalized in the KETER department in several hospitals in&#xD;
      Israel, will be enrolled. 60 patients will receive Ang 1-7 subcutaneously 500 mcg/kg /day. 60&#xD;
      patients will receive placebo : NaCl 0.9% 2 ml -control arm .&#xD;
&#xD;
      Treatment duration: 14 days or until clinical improvement that enables discharge from&#xD;
      hospital.&#xD;
&#xD;
      (the shortest time will be the limiting factor in treatment duration). Follow-up-30 days.&#xD;
      14-30 days after discharge from hospital: we will contact the patient via phone to ask&#xD;
      questions related to any possible adverse reaction to the drug and general health.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The working hypothesis behind this study is that the deleterious effects of SARS-CoV-2 are&#xD;
      largely attributed to the deprivation of the affected target cells from their advantageous&#xD;
      ACE-2-Ang 1-7-MasR machinery on one hand, and to the use of ACE2 as a Trojan horse to infect&#xD;
      and destroy these cells on the other in a vicious feed-forward cycle.&#xD;
&#xD;
      120 confirmed SARS-CoV-2 infected patients who exhibit moderate- clinical symptoms including&#xD;
      dyspnea, cough and fever, hospitalized in the KETER department in several hospitals in&#xD;
      Israel, will be enrolled. 60 patients will receive Ang 1-7 subcutaneously 500 mcg/kg /day. 60&#xD;
      patients will receive placebo : NaCl 0.9% 2 ml -control arm .&#xD;
&#xD;
      Treatment duration: 14 days or until clinical improvement that enables discharge from&#xD;
      hospital.&#xD;
&#xD;
      All patients will be treated by Dexamethasone and Remdesivir, according to the published&#xD;
      guidelines. Moreover, if other promising medications will be approved for COVID-19, the&#xD;
      patients will also be treated by these medications. The current trial will not exclude&#xD;
      promising COVID-19 treatments.&#xD;
&#xD;
      Each patient will be closely followed up, where routine physical sings, respiratory and&#xD;
      hemodynamic parameters will be documented. In addition, the following complications will be&#xD;
      monitored: thromboembolic events, myocarditis, impaired liver function and acute kidney&#xD;
      injury. Allergic reactions will be treated by corticosteroids, antihistamines and adrenalin&#xD;
      if needed. Patients experiencing allergic reactions will be excluded from continuing the&#xD;
      trail.&#xD;
&#xD;
      In addition, biochemical (kidney function tests, electrolytes, liver enzymes, albumin,&#xD;
      protein, ferritin, troponin- 5 ml) and hematological (CBC-(3 ml), and coagulation tests-(3&#xD;
      ml)) analysis will be performed on the day of enrollment and every 3 days . Other blood tests&#xD;
      for immunophenotyping, cytokines, COVID-19 PCR, Angiotensin II (Ang II) levels, Angiotensin&#xD;
      1-7 (Ang 1-7) levels, ACE and ACE-2 will be collected at baseline and at days 6,15,21 and 30&#xD;
      days after enrollment. and every week ( 2 chemistry (10 ml) and 2 CBC tubes (10 ml)).&#xD;
&#xD;
      In addition chest X-ray will be performed at enrollment and at days 6,15,21 and 30 days after&#xD;
      enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for mechanical ventilation</measure>
    <time_frame>Any time from randomization up to 30 days of last study treatment dose</time_frame>
    <description>Patient is intubated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>Any time from randomization up to 30 days of last study treatment dose</time_frame>
    <description>death certificate</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ang 1-7 subcutaneously 500 mcg/kg /day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 0.9% subcutaneously 2.0 cc once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin 1-7</intervention_name>
    <description>Ang 1-7 subcutaneously 500 mcg/kg /day</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Respiratory specimen is positive for SARS-CoV-2 nucleic acid by RT-PCR&#xD;
&#xD;
          2. Fever: Temperature &gt;37.8℃&#xD;
&#xD;
          3. Moderate lung disease, defined by the following respiratory variables (meets one of&#xD;
             the following criteria): lung infiltrates (evident by chest X-ray) not attributable to&#xD;
             other causes plus one of the following:&#xD;
&#xD;
               -  Respiratory rate: RR ≥25 breaths/min&#xD;
&#xD;
               -  Oxygen saturation ≤94 % at rest on room air&#xD;
&#xD;
          4. HBsAg negative, HCV negative; HIV negative&#xD;
&#xD;
          5. Informed consent&#xD;
&#xD;
             -&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
               -  Age &lt;18 years&#xD;
&#xD;
               -  Pregnant or breast-feeding woman or with positive pregnancy test result&#xD;
&#xD;
               -  PaO2/FiO2 ≤100 mmHg / mechanical ventilation&#xD;
&#xD;
               -  Severe organ failure - not expected to survive for &gt;7 days&#xD;
&#xD;
               -  Hemodynamically unstable in the preceding 10 hours (MAP ≤65 mmHg, or SAP &lt;90&#xD;
                  mmHg, DAP &lt;60 mmHg, vasoactive agents are required)&#xD;
&#xD;
               -  Patient on ECMO&#xD;
&#xD;
               -  Patient in other therapeutic clinical trial within 30 days before enrolment&#xD;
&#xD;
               -  Chronic immunosuppression: current autoimmune diseases or patients who received&#xD;
                  immunotherapy within 30 days before enrolment&#xD;
&#xD;
               -  Hematologic malignancy (lymphoma, leukemia, multiple myeloma)&#xD;
&#xD;
               -  Other patient characteristics (not thought to be related to underlying COVID-19)&#xD;
                  that portend a very poor prognosis (e.g, severe congestive heart failure( NYHA&#xD;
                  class III or IV, EF less than 30%,) liver cirrhosis , chronic kidney disease&#xD;
                  stave IV, V(e GFR&lt;30 ml/min), chronic obstructive lung disease: GOLD C,D : ≥2&#xD;
                  exacerbations or ≥1 that required hospitalization, FEV1&lt;50%, GOLD 3,4)&#xD;
&#xD;
               -  Atopic patients suffering from allergies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Etty Kruzel-Davila, Dr.</last_name>
    <phone>+972-53-276-6052</phone>
    <email>e_kruzel@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etty Kruzel-Davila, DR</last_name>
      <phone>+972-53-276-6052</phone>
      <email>e_kruzel@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angiotensin I (1-7)</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

